Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study

Department of Neurology, University of San Francisco, 350 Parnassus Ave, Suite 609, San Francisco, CA 94117, USA.
Journal of Neuro-Oncology (Impact Factor: 2.79). 01/2011; 101(2):267-77. DOI: 10.1007/s11060-010-0255-0
Source: PubMed

ABSTRACT The PRECISE study used convection enhanced delivery (CED) to infuse IL13-PE38QQR in patients with recurrent glioblastoma multiforme (GBM) and compared survival to Gliadel Wafers (GW). The objectives of this retrospective evaluation were to assess: (1) catheter positioning in relation to imaging features and (2) to examine the potential impact of catheter positioning, overall catheter placement and imaging features on long term clinical outcome in the PRECISE study. Catheter positioning and overall catheter placement were scored and used as a surrogate of adequate placement. Imaging studies obtained on day 43 and day 71 after resection were each retrospectively reviewed. Catheter positioning scores, catheter overall placement scores, local tumor control and imaging change scores were reviewed and correlated using Generalized Linear Mixed Models. Cox PH regression analysis was used to examine whether these imaging based variables predicted overall survival (OS) and progression free survival (PFS) after adjusting for age and KPS. Of 180 patients in the CED group, 20 patients did not undergo gross total resection. Of the remaining 160 patients only 53% of patients had fully conforming catheters in respect to overall placement and 51% had adequate catheter positioning scores. Better catheter positioning scores were not correlated with local tumor control (P = 0.61) or imaging change score (P = 0.86). OS and PFS were not correlated with catheter positioning score (OS: P = 0.53; PFS: P = 0.72 respectively), overall placement score (OS: P = 0.55; PFS: P = 0.35) or imaging changes on day 43 MRI (P = 0.88). Catheter positioning scores and overall catheter placement scores were not associated with clinical outcome in this large prospective trial.

Download full-text


Available from: Sabine Mueller, Jun 27, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin 13 receptor α 2 (IL-13Rα2) is a glioblastoma multiforme (GBM)-associated plasma membrane receptor, a brain tumor of dismal prognosis. Here, we isolated peptide ligands for IL-13Rα2 with use of a cyclic disulphide-constrained heptapeptide phages display library and 2 in vitro biopanning schemes with GBM cells that do (G26-H2 and SnB19-pcDNA cells) or do not (G26-V2 and SnB19-asIL-13Rα2 cells) over-express IL-13Rα2. We identified 3 peptide phages that bind to IL-13Rα2 in cellular and protein assays. One of the 3 peptide phages, termed Pep-1, bound to IL-13Rα2 with the highest specificity, surprisingly, also in a reducing environment. Pep-1 was thus synthesized and further analyzed in both linear and disulphide-constrained forms. The linear peptide bound to IL-13Rα2 more avidly than did the disulphide-constrained form and was efficiently internalized by IL-13Rα2-expressing GBM cells. The native ligand, IL-13, did not compete for the Pep-1 binding to the receptor and vice versa in any of the assays, indicating that the peptide might be binding to a site on the receptor different from the native ligand. Furthermore, we demonstrated by noninvasive near infrared fluorescence imaging in nude mice that Pep-1 binds and homes to both subcutaneous and orthotopic human GBM xenografts expressing IL-13Rα2 when injected by an intravenous route. Thus, we identified a linear heptapeptide specific for the IL-13Rα2 that is capable of crossing the blood-brain tumor barrier and homing to tumors. Pep-1 can be further developed for various applications in cancer and/or inflammatory diseases.
    Neuro-Oncology 09/2011; 14(1):6-18. DOI:10.1093/neuonc/nor141 · 5.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: An axisymmetric biphasic finite element model is proposed to simulate the backflow that develops around the external boundary of the catheter during flow-controlled infusions. The model includes both material and geometric nonlinearities and special treatments for the nonlinear boundary conditions used to represent the forward flow from the catheter tip and the axial backflow that occurs in the annular gap that develops as the porous medium detaches from the catheter. Specifically, a layer of elements with high hydraulic conductivity and low Young's modulus was used to represent the nonlinear boundary condition for the forward flow, and another layer of elements with axial hydraulic conductivity consistent with Poiseuille flow was used to represent the backflow. Validation of the model was performed by modifying the elastic properties of the latter layer to fit published experimental values for the backflow length and maximum fluid pressure obtained during infusions into agarose gels undertaken with a 0.98-mm-radius catheter. Next, the finite element model predictions showed good agreement with independent experimental data obtained for 0.5-mm-radius and 0.33-mm-radius catheters. Compared to analytical models developed by others, this finite element model predicts a smaller backflow length, a larger fluid pressure, and a substantially larger percentage of forward flow. This latter difference can be explained by the important axial flow in the tissue that is not considered in the analytical models. These results may provide valuable guidelines to optimize protocols during future clinical studies. The model can be extended to describe infusions in brain tissue and in patient-specific geometries. [DOI: 10.1115/1.4007311]
    01/2012; 8(1):011017. DOI:10.1115/1.4007311
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Brain tumors are a unique class of cancers since they are anatomically shielded from normal immunosurveillance by the blood-brain barrier, lack a normal lymphatic drainage system and reside in a potently immunosuppressive environment. Of the primary brain cancers, glioblastoma multiforme (GBM) is the most common and aggressive in adults. Although treatment options include surgery, radiation and chemotherapy, the average lifespan of GBM patients remains at only 14.6 months post-diagnosis. AREAS COVERED: A review of key cellular and molecular immune system mediators in the context of brain tumors including TGF-β, cytotoxic T cells, Tregs, CTLA-4, PD-1 and IDO is discussed. In addition, prognostic factors, currently utilized immunotherapeutic strategies, ongoing clinical trials and a discussion of new or potential immunotherapies for brain tumor patients are considered. EXPERT OPINION: Current drugs that improve the quality of life and overall survival in patients with brain tumors, especially for GBM, are poorly effective. This disease requires a reanalysis of currently accepted treatment strategies, as well as newly designed approaches. Here, we review the fundamental aspects of immunosuppression in brain tumors, new and promising immunotherapeutic drugs as well as combinatorial strategies that focus on the simultaneous inhibition of immunosuppressive hubs, both in immune and brain tumor cells, which is critical to consider for achieving future success for the treatment of this devastating disease.
    Expert Opinion on Emerging Drugs 04/2012; 17(2):181-202. DOI:10.1517/14728214.2012.679929 · 3.28 Impact Factor